Overview

Effects Zulresso on Postpartum Psychosis

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, proof of concept trial to investigate the efficacy, safety and tolerability of Zulresso (brexanolone) administered to adult female subjects diagnosed with postpartum psychosis. This study will provide critical pilot data to determine whether there is similar treatment efficacy among patients with postpartum psychosis as observed to date in patients with postpartum depression.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
Sage Therapeutics
Treatments:
Brexanolone